Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.65 |
| ▸ | HTR1A | P08908 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11712364 | 0.88 | DRD2 (0.72) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL11730898 | 0.88 | DRD2 (0.72) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL11712503 | 0.88 | DRD2 (0.72) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL11801298 | 0.88 | DRD2 (0.72) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL11365759 | 0.87 | DRD2 (0.75) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL8401002 | 0.87 | DRD2 (0.75) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL11804646 | 0.87 | DRD2 (0.74) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL29419576 | 0.87 | HTT (0.63) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL32691694 | 0.86 | HTR1A (0.60) | DRD2DRD1DRD3MEN1GAA | |
| SCHEMBL8336449 | 0.86 | DRD2 (0.69) | DRD2DRD1DRD3MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136858-A | Compounds useful as ALCAT1 inhibitors | 中美博瑞纳制药有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-110709394-B | Compounds useful as ALCAT1 inhibitors | 中美博瑞纳制药有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9427418-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9051267-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150087712-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2015-03-26 | — | — | US | disclosed |
| EP-2747562-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | Gtx, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140171468-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2013043304-A9 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2012-03-29 | — | — | US | disclosed |
| WO-2011106317-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010096801-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1954670-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007062230-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GNRHR, LHCGR, SHBG | DRD2 4641/4885DRD1 4761/4885DRD3 4135/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | DRD2 4126/4885DRD1 4089/4885DRD3 3622/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | DRD2 4126/4885DRD1 4089/4885DRD3 3622/4885 |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, GNRHR, FSHR | DRD2 2996/4885DRD1 4116/4885DRD3 2458/4885 |
| US-20140171468-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, GNRHR, FSHR | DRD2 2996/4885DRD1 4116/4885DRD3 2458/4885 |
| US-20150087712-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, AR, NR5A1 | DRD2 4709/4885DRD1 4807/4885DRD3 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.